Scientific Committee & Invited Faculty

John Gribben MD, DSc, FRCPath, FRCP, FMedSci is a Consultant Haematologist and Medical Oncologist at Barts Cancer Institute, Queen Mary University of London, London, UK.

Professor Gribben completed his MD at the University of Glasgow, and his DSc at University College London. He continued his training at the Dana-Farber Cancer Institute, Harvard Medical School and was appointed to the Faculty at Harvard Medical School before returning to London in 2005.

Professor Gribben’s primary research interests include the immunotherapy of cancer (including stem cell transplantation), the identification of B-cell tumor antigens, and the detection and treatment of measurable residual disease (MRD) in leukemia and lymphoma.

David Maloney MD, PhD is the Leonard and Norma Klorfine Endowed Chair for Clinical Research at the Fred Hutchinson Cancer Research Center, and the Medical Director at the Bezos Family Immunotherapy Clinic, Seattle Cancer Care Alliance in Washington, USA. He is also a Professor of Medicine at the University of Washington.

Dr Maloney completed his MD, PhD and a Medical Oncology fellowship at Stanford University, California. He also undertook an Internal Medicine fellowship at Brigham and Women’s Hospital in Massachusetts.

Dr Maloney’s research is focused on the development of immunotherapies for patients with lymphoid cancers, including lymphomas, leukemias and myeloma. He is currently leading a clinical trial that is evaluating the use of CAR-T cells for patients with CD19 positive malignancies, including ALL, CLL and NHL.

Caron Jacobson MD is the Medical Director of the Immune Effector Cell Therapy Program at the Dana-Farber/Brigham and Women’s Cancer Center in Massachusetts, USA. She is also an Assistant Professor of Medicine at Harvard Medical School.

Dr Jacobson completed her medical degree at the Columbia College of Physicians and Surgeons in New York, USA, followed by residencies at Columbia-Presbyterian Medical Center and NewYork-Presbyterian Hospital. She completed her fellowship at the Dana-Farber Cancer Institute where she now works.

Frederick Locke MD is a medical oncologist and translational researcher in the Department of Blood and Marrow Transplant and Cellular Immunotherapy at the Moffitt Cancer Center in Tampa, Florida.

Dr Locke completed his MD at Wayne State University, Detroit, Michigan. He then undertook a residency at Detroit Medical Center and a Haematology/Oncology fellowship at the University of Chicago Medical Center.

Dr Locke’s research focuses on developing strategies to promote T cell responses against tumour associated antigens for patients with lymphoma and multiple myeloma. He is a lead investigator for two national multi-center phase I/II studies treating aggressive lymphoma patients with anti-CD19 CAR T cells and the site PI of a randomized multi-center trial testing infusion of tumor (marrow) infiltrating lymphocytes for multiple myeloma.

Noelle Frey, MD, is an assistant professor of medicine at the Hospital of the University of Pennsylvania, Philadelphia, PA. She has clinical expertise in leukemia, MDS, lymphoma and ASCT.

Dr Frey completed her MD at Columbia University College of Physicians and Surgeons, New York City, NY. She then undertook a fellowship and residency at the University of Pennsylvania Health System. In addition, Dr Frey completed an MS in Clinical Epidemiology & Biostatistics from the University of Pennsylvania in 2012.

Dr Frey’s research focuses on early phase clinical trial design and translational research for patients with hematologic malignancies and those undergoing ASCT. She is involved in numerous clinical trials, including exciting CAR T-cell trials in ALL and CLL. Dr Frey has many publications in this area, including the cellular kinetics of CAR T-cell treatment and cytokine release syndrome.

Saar Gill, MD, is an Assistant Professor of Medicine at the Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA.

Dr Gill obtained his medical degree from the University of Melbourne, Melbourne, Australia. He undertook residencies in Internal Medicine at St Vincent’s Hospital, Melbourne, Australia and Haematology at the Peter MacCallum Cancer Centre and at the Royal Melbourne Hospital, Melbourne, Australia.

Dr Gill then undertook a postdoctoral fellowship in the laboratory of Dr Robert Negrin at Stanford University, California, USA, followed by a fellowship in BMT and Cellular Therapy under Dr David Porter at the University of Pennsylvania, Philadelphia, USA. He also worked in the laboratory of Dr Michael Kalos, focusing on chimeric antigen receptor T cells for the treatment of acute myeloid leukemia before forming his own research group.

Yi Lin MD, PhD is a clinical haematologist at the Mayo Clinic in Minnesota, USA.

Dr Yin completed her PhD in Biomedical Engineering at the University of Minnesota, and then undertook her MD at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. She undertook her residency and a fellowship in Haematology and Medical Oncology at the Mayo Clinic College of Medicine where she now works.

Bijal Shah, MD, is a Hematologist and Oncologist, associated with the Moffitt Cancer Center, Florida, USA.

Dr Shah received his MD from the University of South Florida, Florida, USA. He then undertook a residency in Internal Medicine and Pediatrics at Duke University, North Carolina, USA, followed by a training fellowship at the Moffitt Cancer Center where he currently works.

Claire Roddie, MD, PhD, is a Consultant Haematologist and Honorary Senior Lecturer in Haematology at University College London, London, UK.

Dr Roddie completed her PhD in Cellular Immunotherapy at University College London in the laboratory of Professor Karl Peggs. She then undertook a Clinician Scientist post in Dr Martin Pule’s Laboratory to work on the UCL CAR T-cell program.

John, DiPersio, MD, PhD, is Professor of Medicine at Washington University School of Medicine, Missouri, USA. He is also the Director for the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine, Missouri, USA.

Dr DiPersio obtained his medical degree and PhD in Microbiology from the University of Rochester, New York, USA. He then carried out an internship and residency at Parkland Memorial Hospital, UT Southwestern Medical Centre, Texas, USA, followed by a fellowship in the Division of Hematology-Oncology at University of California Los Angeles, California, USA.

Jordan Gauthier, MD, is an assistant member at Fred Hutchinson Cancer Research Center, Washington, USA.

Dr Gauthier received his MD from Université de Rennes I, Rennes, France, before carrying out a MSc in Biomedical Sciences at The Vrije Universiteit Brussel, Brussels, Belgium. He carried out a residency and fellowship at the CHRU Lille Centre Biologie Pathologie, in France and a further fellowship at the Seattle Cancer Care Alliance, Washington, USA.

Joseph Fraietta, PhD, is an Assistant Professor of Microbiology at the Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.

Dr Fraietta obtained his PhD in Microbiology and Immunology from the Drexel University College of Medicine, Philadelphia, USA under the supervision of Dr Peter D. Katsikis.

Krina Patel, MD, is an Assistant Professor at the Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Texas USA.

Dr Patel obtained her medical degree from the University of Texas Southwestern Medical School, Texas, USA. She carried out a residency in Internal Medicine at The University of Texas UT Health, Texas, USA before carrying out a fellowship in Hematology/Oncology at the MD Anderson Cancer Center.

Loretta J. Nastoupil, MD, is an assistant professor at The University of Texas, MD Anderson Cancer Center, Texas, USA. She is also the Director of the Department of Lymphoma / Myeloma.

Dr Nastoupil obtained her medical degree from the University of Texas Southwestern Medical School, Texas, USA. She then completed an internal medicine residency at Washington University, Barnes-Jewish Hospital, Missouri, USA followed by a Hematology-Medical Oncology fellowship at Emory University, Georgia, USA.

Matthew Frigault, MD, is a Medical Oncologist in the Hematologic Malignancy Program at the Massachusetts General Hospital Cancer Center, Massachusetts, USA, as well as Administrative Director of the Cellular Therapy Service. He is also an instructor at Harvard Medical School, Massachusetts, USA.

Dr Frigault completed his MD at the University of Pennsylvania, Philadelphia, USA. He completed his oncology fellowship at the combined Massachusetts General Hospital / Dana Farber Cancer Institute where he worked with Dr Marcela Maus. He also carried out post-graduate training at the Johns Hopkins University, Maryland, USA in Dr Ivan Borrelo’s laboratory.

Nirali Shah, MD, is an Associate Research Physician at Johns Hopkins University, Maryland, USA.

Dr Shah obtained her medical degree from the University of Illinois College of Medicine, Illinois, USA. She then completed a dual residency program in Internal Medicine and Pediatrics at the Children’s Hospital Boston and Massachusetts General Hospital, Massachusetts, USA.

She then joined the Pediatric Hematology and Oncology Fellowship training program between the National Cancer Institute, Pediatric Oncology Branch and Johns Hopkins University where she currently works.

Rizwan Romee, MD, is an Associate Professor of Medicine at Harvard Medical School, Massachusetts, USA and also the Director of Haploidentical Donor Transplantation Program.

Dr Romee, received his medical degree from Govt. Medical College, Srinagar, India. He then completed his postgraduate training and Hematology and Oncology fellowship at the University of Minnesota. He carried out postdoctoral training in Dr Jeffrey S. Miller’s laboratory at University of Minnesota and Dr Todd Fehniger’s laboratory at Washington University School of Medicine, Washington, USA.

Sham Mailankody, MBBS, is a Medical Oncologist at the Memorial Sloan Kettering Cancer Center, New York, USA.

Dr Mailankody was awarded his medical degree from K.S. Hedge Medical Academy, Mangaluru, India. He then completed his residency in Internal Medicine at the Med Star Washington Hospital Center, Washington D.C., Washington, before carrying out a fellowship in Medical Oncology at the National Institutes of Health Clinical Center, Bethesda, Maryland.

William Go, MD, PhD is a member of the leadership team of A2 Biotherapeutics, where he serves as Senior Vice President of Clinical Development.

He initially gained a biology degree from Carleton College, and later trained in medicine and achieved a doctorate from the University of California.